Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2

Dermatologic Therapy
Wei-Li MaSung-Hsin Kuo

Abstract

Immune checkpoint blockades were reported to result in clinical responses in inoperable and metastatic cutaneous squamous cell carcinoma (cSCC). This report describes an 87-year-old woman with recurrent cSCC that was initially responsive to cetuximab (the monoclonal antibody against epithelial growth factor receptor) but eventually became refractory to cetuximab and multiple subsequent salvage chemotherapy regimens. Next-generation sequencing of the tumor discovered three single-nucleotide mutations in TP53, copy number amplification in Src, and a heterozygous deletion in BRCA2. Because of the high mutation burden of her neoplasm (35.2 mutations per megabase), we treated her with a programmed death-1 (PD-1) checkpoint inhibitor, pembrolizumab, for 10 months. The tumor regressed 3 months later and complete pathological remission was achieved 10 months after starting treatment. As of writing, the patient has been disease free for 17 months after discontinuing treatment. This is the first reported case of heterozygous deletion of BRCA2 in cSCC. The high mutation burden and BRCA2 mutation might explain why this tumor was highly sensitive to anti-PD-1 treatment.

References

Apr 25, 2003·The New England Journal of Medicine·Sylvie EuvrardAlain Claudy
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eve MaubecMarie-Françoise Avril
Apr 10, 2012·Seminars in Oncology·Ronald C DeConti
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Aug 6, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M C FooteS V Porceddu
Oct 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Curtis R PickeringMitchell J Frederick
Jan 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yvonne Y LiPeter S Hammerman
Apr 4, 2015·Science·Ton N Schumacher, Robert D Schreiber
Jul 30, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alexander StratigosUNKNOWN European Organization for Research and Treatment of Cancer (EORTC)
Oct 2, 2017·Journal of the American Academy of Dermatology·William N WilliamEdward S Kim
Dec 21, 2017·The New England Journal of Medicine·Mark YarchoanElizabeth M Jaffee
Jun 5, 2018·The New England Journal of Medicine·Michael R MigdenMatthew G Fury
Apr 21, 2019·Cancer Immunology Research·Aaron M GoodmanRazelle Kurzrock

❮ Previous
Next ❯

Citations

Dec 10, 2020·International Journal of Molecular Sciences·Anja WesselyMarkus Vincent Heppt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.